Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028768 (Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00492089Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerSupportive Care